Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06516965 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 60 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Recruiting → Active, Not Recruiting Enrollment target: estimated 330 to confirmed 346 · Site details revised at 119 of 119 sitesv60 Show 2 more changesShow less
    • Enrollment target: estimated 330 to confirmed 346
    • Site details revised at 119 of 119 sites
  2. Study sites: 121 to 119v59
  3. Study sites: 120 to 121v58
  4. Site details revised at 2 of 120 sitesv57
  5. Site details revised at 1 of 120 sitesv56
Show 45 earlier versionsHide 45 earlier versions
  1. Site details revised at 4 of 120 sitesv55
  2. Site details revised at 4 of 120 sitesv54
  3. Site details revised at 2 of 120 sitesv53
  4. Site details revised at 2 of 120 sitesv52
  5. Site details revised at 1 of 120 sitesv51
  6. Site details revised at 1 of 120 sitesv50
  7. Site details revised at 1 of 120 sitesv49
  8. Study sites: 119 to 120v48
  9. Study sites revised (119)v47 See this version in full on ClinicalTrials.gov ↗
  10. Study sites revised (119)v46 See this version in full on ClinicalTrials.gov ↗
  11. Study sites: 139 to 119 Primary completion date: Sep 11, 2026 to Oct 19, 2026 · Completion date: Jun 2, 2027 to May 3, 2027v45 Show 2 more changesShow less
    • Primary completion date: Sep 11, 2026 to Oct 19, 2026
    • Completion date: Jun 2, 2027 to May 3, 2027
  12. Study sites: 138 to 139v44
  13. Study sites: 136 to 138v43
  14. Re-verified, no change to tracked fieldsv42
  15. Site details revised at 1 of 136 sitesv41
  16. Study sites revised (136)v40 See this version in full on ClinicalTrials.gov ↗
  17. 2 versions Re-verified since Jun 27, 2025, no change to tracked fieldsv38-v39
  18. Study sites revised (136)v37 See this version in full on ClinicalTrials.gov ↗
  19. Site details revised at 1 of 136 sitesv36
  20. Study sites: 135 to 136v35
  21. Site details revised at 6 of 135 sitesv34
  22. Site details revised at 2 of 135 sitesv33
  23. Site details revised at 3 of 135 sitesv32
  24. Site details revised at 2 of 135 sitesv31
  25. Site details revised at 10 of 135 sitesv30
  26. Study sites revised (135)v29 See this version in full on ClinicalTrials.gov ↗
  27. Site details revised at 2 of 135 sitesv28
  28. Site details revised at 4 of 135 sitesv27
  29. Site details revised at 13 of 135 sitesv26
  30. Site details revised at 8 of 135 sitesv25
  31. Site details revised at 4 of 135 sitesv24
  32. Site details revised at 2 of 135 sitesv23
  33. Study sites: 136 to 135v22
  34. Site details revised at 3 of 136 sitesv21
  35. Study sites revised (136)v20 See this version in full on ClinicalTrials.gov ↗
  36. Study sites: 135 to 136v19
  37. Study sites: 134 to 135v18
  38. Site details revised at 1 of 134 sitesv17
  39. Site details revised at 3 of 134 sitesv16
  40. Site details revised at 3 of 134 sitesv15
  41. Study sites: 133 to 134v14
  42. Site details revised at 1 of 133 sitesv13
  43. Site details revised at 2 of 133 sitesv12
  44. Site details revised at 1 of 133 sitesv11
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Incyte
94 trials monitored
See 9 trials at risk
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Trial Details
NCT Number NCT06516965
Lead Sponsor Incyte Corporation
Conditions Prurigo Nodularis
Enrollment 346 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov